ethyl,4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate | 854044-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl,4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate
• 英文别名: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid ethyl ester；Ethyl 4-cyano-1-((2-(trimethylsilyl)ethoxy)-methyl)-1H-imidazole-2-carboxylate；ethyl 4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate
• CAS: 854044-52-3
• 化学式: C₁₃H₂₁N₃O₃Si
• 分子量: 295.414
• InChiKey: RQMDFPGLTPLVTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  77.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl,4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate 在 四(三苯基膦)钯 氢氧化钾 、 乙醇 、 水 、 sodium carbonate 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.17h， 生成 4-cyano-1H-imidazole-2-carboxylic acid (4'-amino-3-cyclohex-1-enyl-biphenyl-4-yl)-amide trifluoroacetic acid salt
  参考文献：
  名称：

  WO2007/123516

  摘要：

  公开号：
• 作为产物：
  描述：

  氰基甲酸乙酯 在 异丙基氯化镁 、 氯化铵 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.17h， 以74%的产率得到ethyl,4-cyano-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate
  参考文献：
  名称：

  SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR

  摘要：

  本发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括管理法尼基转移酶抑制剂和从公式I'的化合物中选择的FLT3激酶抑制剂。 本发明包括用于治疗处于发展细胞增殖障碍或与FLT3相关障碍风险（或易感性）的受试者的预防和治疗方法。

  公开号：

  US20060281788A1

文献信息

• SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR
  申请人：Baumann Andrew Christian

  公开号：US20060281788A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括管理法尼基转移酶抑制剂和从公式I'的化合物中选择的FLT3激酶抑制剂。 本发明包括用于治疗处于发展细胞增殖障碍或与FLT3相关障碍风险（或易感性）的受试者的预防和治疗方法。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20070249593A1

  公开（公告）日：2007-10-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I化合物：其中Z、X、J、R2和W在说明书中规定，以及抑制蛋白酪氨酸激酶，尤其是c-fms激酶的溶剂化物、水合物、互变异构体和药用盐。治疗自身免疫病；和治疗具有炎症成分的疾病；治疗来自卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；和治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症性和神经性疼痛；以及骨质疏松症、佩吉特病，以及骨吸收介导病状的其它疾病，包括类风湿性关节炎、其它形式的炎症性关节炎、骨关节炎、假体失败、溶骨肉瘤、骨髓瘤和骨转移瘤，也提供了式I化合物。
• C-fms kinase inhibitors
  申请人：Player R. Mark

  公开号：US20050131022A1

  公开（公告）日：2005-06-16

  The invention is directed to compounds of Formulae I: wherein A, R 1 , R 2 , R 3 , R 4 , X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

  该发明涉及以下式I的化合物：其中A、R1、R2、R3、R4、X和W如规范中所述，以及其溶剂合物、水合物、互变体或药学上可接受的盐，可以抑制蛋白酪氨酸激酶，尤其是c-fms激酶。
• Cyano-Substituted 2-Carboxyimidazoles: Synthesis of 4-Cyano-1-{[2-(tri­meth­ylsilyl)ethoxy]methyl}-1<i>H</i>-imidazole-2-carboxylate Potassium Salt
  作者：Mark Wall、Carsten Schubert、Carl Illig

  DOI：10.1055/s-0028-1083173

  日期：——

  synthesis of potassium 4-cyano-1-[2-(trimethylsilyl)ethoxy]methyl} -1 H-imidazole-2-carboxylate (2) is demonstrated where the carboxylate group is introduced via bromine-magnesium exchange on a SEM-protected cyanoimidazole followed by reaction with ethyl cyanoformate. The synthesis includes the equilibration of a regioisomeric mixture of SEM-protected imidazoles to give a single product.

  报道了单氰基取代的2-羧基咪唑的第一个例子。4-cyano-1-[2-(trimethylsilyl)ethoxy]methyl} -1 H-imidazole-2-carboxylate (2) 的合成证明，其中羧酸根基团是通过 SEM- 上的溴-镁交换引入的保护氰基咪唑，然后与氰基甲酸乙酯反应。该合成包括平衡 SEM 保护的咪唑的区域异构混合物以产生单一产物。
• PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES
  申请人：Janssen Pharmaceutica NV

  公开号：US20140046072A1

  公开（公告）日：2014-02-13

  The present invention is directed to a process for the preparation of heterocyclic ester derivatives of formula I wherein A 1 , SEM, and W 1 are as defined herein. Such compounds are useful as intermediates in the synthesis of derivatives useful as protein tyrosine kinase inhibitors, more particularly inhibitors of c-fms kinase.

  本发明涉及一种制备式I的杂环酯衍生物的方法，其中A1，SEM和W1如本文所定义。这些化合物可用作合成蛋白酪氨酸激酶抑制剂的衍生物的中间体，更具体地是c-fms激酶的抑制剂。